Drugs / KB301
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04540900 Comparator | Oct 2020 → Oct 2024 overdue | — | Krystal Biotech, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04540900 ↗ |
| Route | Other | “two (2) injectable doses of KB301” NCT04540900 ↗ |